Ezutromid, Catalog: B1248

Alternate Names 5-(ethylsulfonyl)-2-(naphthalen-2-yl)benzo[d]oxazole; BMN195

Appearance Light brown solid

CAS # 945531-77-1

Molecular Formula C₁₉H₁₅NO₃S 

Molecular Weight 337.39

Purity ≥ 98% by HPLC

Solubility DMSO (>10 mg/ml)

SMILES CCS(=O)(=O)C1=CC2=C(C=C1)OC(=N2)C3=CC4=CC=CC=C4C=C3

InChi InChI=1S/C19H15NO3S/c1-2-24(21,22)16-9-10-18-17(12-16)20-19(23-18)15-8-7-13-5-3-4-6-14(13)11-15/h3-12H,2H2,1H3

InChi Key KSGCNXAZROJSNW-UHFFFAOYSA-N

PubChem CID 25109292

Storage Conditions -20°C

Shipping Conditions Gel Pack

Usage For Research Use Only! Not For Use in Humans.

Handling Do not take it internally. Wear a glove and mask when handling the product. Protect from air and moisture.

Ezutromid is a first orally available drug for the treatment of Duchenne muscular dystrophy (DMD), a lethal, X-linked muscle wasting disease caused due to lack of dystrophin-a cytoskeleton protein. Ezutromid has shown potential as disease modifying treatment for DMD patients irrespective of their gene mutation. Ezutromid acts on utrophin modulation and has potential to slow down or stop the progression of DMD.